Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

R5 Integrase Study in HIV-1 Naive Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2012 by University of Maryland.
Recruitment status was:  Recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Robert Redfield, MD, University of Maryland Identifier:
First received: September 16, 2010
Last updated: November 8, 2012
Last verified: November 2012

This is a pilot, open-label study of raltegravir and maraviroc in combination for the treatment of antiretroviral naïve patients. The study will enroll 10 antiretroviral naïve patients with CD4 counts ≥ 350 and viral loads > 5,000. The subjects will be followed for 48 weeks. The combination of these two agents has the potential to be a potent regimen with minimal metabolic complications. However, they have not been studied in combination previously.

This pilot study proposes to evaluate this combination in antiretroviral naïve patients to document the safety and efficacy of this combination in order to provide clinicians with a treatment regimen that minimizes the risk of metabolic complications.

Condition Intervention
HIV Infections
Drug: Raltegravir and Maraviroc in combination

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Raltegravir and Maraviroc in Combination for the Treatment of Antiretroviral Naïve HIV-1 Infected Patients

Resource links provided by NLM:

Further study details as provided by University of Maryland:

Primary Outcome Measures:
  • Viral Load [ Time Frame: 48 months ]
    Percentage of subjects with HIV-1 viral load < 50 copies/ml

Secondary Outcome Measures:
  • Viral Suppression [ Time Frame: 48 months ]
    Time to attainment of virologic suppression

Estimated Enrollment: 10
Study Start Date: September 2010
Estimated Study Completion Date: September 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Open Label Drug: Raltegravir and Maraviroc in combination

Raltegravir 400 mg tablet twice a day, ~12 hours (10 to 14 hours) apart

Maraviroc 300 mg tablet twice a day, ~12 hours (10 to 14 hours) apart

Other Names:
  • Raltegravir (Isentress)
  • Maraviroc(Selzentry)


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 infection
  • CD4 count ≥ 350
  • RNA > 5,000
  • CCR5 tropic virus
  • Baseline genotype without significant mutations known to confer antiretroviral drug resistance to currently licensed antiretroviral agents
  • Antiretroviral naïve (< 7 days of experience)
  • 18-75 years of age
  • Subject able to provide informed consent for the study
  • Women of child-bearing age agree to remain abstinent or use (or have their partner use) an acceptable method of birth control throughout the study. Acceptable method of birth control is defined as intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy.

Exclusion Criteria:

  • Dual/mixed tropic virus,
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limits of normal;
  • Total bilirubin >1.5 mg/dL,
  • Women pregnant or breastfeeding,
  • History of malignancy
  • Enrollment in an experimental protocol with concomitant use of drugs known to impact or be impacted in terms of pk or drug-drug interactions with either raltegravir or maraviroc. This includes inducers of UGT1A1 ( such as rifampin, phenytoin, Phenobarbital rifabutin, St. John's wart) as well as CYP3A inhibitors (such as ketoconazole, itraconazole, clarithromycin , nefazodone and telithromycin) and CYP3A inducers (such as rifampin, carbamazepine, Phenobarbital and phenytoin)
  • Enrollment in an experimental protocol having received investigational agents(antiretroviral or non-antiretroviral) within 30 days of study enrollment
  • Chronic active hepatitis B infection
  • Subject has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study, such that it is not in the best interest of the patient to participate.
  • Subject is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
  • Subject requires or is anticipated to require any of the prohibited medications noted in the protocol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01204905

Contact: Colleen Boyce, RN 410-706-0100

United States, Maryland
University of Maryland, Institute of Human Virology Recruiting
Baltimore, Maryland, United States, 21201
Contact: Colleen Boyce, RN    410-706-0100      
Principal Investigator: Robert Redfield, MD         
Sponsors and Collaborators
University of Maryland
Merck Sharp & Dohme Corp.
Principal Investigator: Robert R. Redfield, MD University of Maryland
  More Information

Responsible Party: Robert Redfield, MD, Associate Director of the Institute of Human Virology, University of Maryland, Baltimore, University of Maryland Identifier: NCT01204905     History of Changes
Other Study ID Numbers: HP-00045769
Study First Received: September 16, 2010
Last Updated: November 8, 2012

Keywords provided by University of Maryland:
Viral Load
Human Immunodeficiency Virus (HIV)

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
HIV Integrase Inhibitors
Integrase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
CCR5 Receptor Antagonists processed this record on April 25, 2017